2022-RA-585-ESGO Come back to the future: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification. (20th October 2022)

• Record Type: Journal Article
• Authors: Perrone, Emanuele; Capasso, Ilaria; de Felice, Francesca; Dinoi, Giorgia; Bizzarri, Niccolo; Foresta, Aniello; Lorusso, Domenica; Scambia, Giovanni; Fanfani, Francesco
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A99
• Page End: A99
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.217
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The estrogens receptor (ER) expression in endometrial cancer (EC) is known to be associated with prognosis. However, its role was not included in the latest molecular risk classification system. The aim of this study is to assess the impact of ER profile on oncological outcomes in the new EC risk classification. Methodology: Retrospective IHC analyses were conducted in a large series of ECs, studying the presence/absence of hormone receptors and other molecular (i.e p53 and mismatch mutational status), histopatological and clinical outcome. The ER status was correlated with molecular, histological, clinical and prognostic data. Results: 891 EC-patients were included in the study (211 ER-negative and 680 ER-positive). The ER-negative phenotype was linked with an unfavorable pathologic-clinical profile (grading, histotype, LVSI, stages, etc) and with high and advanced risk class (64.5vs 27%) (p<0.05). Molecular analysis in ER-negative compared to ER-positive showed greater p53-mutation rate (39% vs 10%), similar MMR-deficiency (20% vs 23.5%), fewer MMR-stability (38% vs 65%) ( table1 ). Noteworthy, simple regression demonstrated that ER-negativity was related to worse OS and DFS, regardless of p53 status; whereas for ER-positive, the prognosis was strongly associated to molecular status (p<0.05). When associated to risk classes, ER-negative EC patients had the worst outcomes compared to the ER-positive counterparts, especially for intermediate, high-intermediate and high-risk classes (p<0.05) ( figure1 ). Conclusion: We demonstrated that the ER status has a significant impact on oncological outcomes, regardless of risk class and p53/MMR status. On these bases, we advise to include ER assessment in featured EC risk classification system.